Connect with us

Hi, what are you looking for?


Gilead stock is not out of room to run just yet: Truist

Gilead Sciences Inc (NASDAQ: GILD) ended this week up nearly 20% after reporting its quarterly results that handily topped Street estimates and subsequently winning an upgrade from a Truist analyst.

Gilead stock could climb another 15%

Robyn Karnauskas now sees upside in the biotech firm to $91 – up another 15% from here.

She recommends buying Gilead stock primarily for its “undervalued” oncology pipeline. In 2020, Gilead partnered with Arcus Biosciences to develop a chemotherapy-free treatment for lung cancer.

Street expects that regimen of three drugs to peak at $200 million in adjusted sales. Karnauskas, though, is convinced it could eventually be bringing in $1.50 billion for Gilead Sciences Inc.

Oncology is where we are differentiated vs the Street. We believe GILD has a unique oncology platform; we expect the pipeline to continue to emerge and grow over the next 12 to 18 months.

Gilead stock currently sits at a year-to-date high.

Gilead Sciences raised its full year outlook

Other than that, Karnauskas is also bullish on Trodelvy – Gilead’s breast cancer drug that she said has potential to generate as much as $4.5 billion in annual sales.

Nonetheless, the Truist analyst does acknowledge that oncology could take a little bit of time to play out. In the meantime, she expects the core “HIV” business to drive growth, especially after Gilead raised prices for Biktarvy and Descovy earlier in 2022.

On Friday, the Nasdaq-listed firm raised its outlook for the full year. It now forecasts $25.9 billion to $26.2 billion in sales on up to $3.55 of earnings per share.

Gild stock also pays a dividend yield of 3.68%.

The post Gilead stock is not out of room to run just yet: Truist appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...


    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...


    U.S. District Court Judge Reed O’Connor recently ruled to uphold the rights of employers granted in the Religious Freedom Restoration Act, rather than uphold...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023